Beijing, Shanghai & Boston, Jul 26, 2024 — Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the first patient has been dosed in its Phase I/IIa clinical trial of JAB-30355, a p53 Y220C reactivator, in patients with solid tumors.
P53 is the most frequently altered gene in human cancers, with mutations presented in approximately 50% of all invasive tumors. JAB-30355 is an orally bioavailable small molecule designed to treat patients with solid tumors harboring p53 Y220C mutation.
According to the preclinical results presented by Jacobio at AACR 2024, JAB-30355 is a potent and selective p53 Y220C reactivator. JAB-30355 exhibited dose-dependent anti-tumor activity in multiple CDX and PDX models, with overall good tolerability. The synergistic effect was observed when combined with other anti-cancer agents, indicating a broad potential for combinational therapy with JAB-30355.
Currently, there is only one p53 Y220C activator in phase II stage worldwide. The clinical study of JAB-30335 is being conducted in China and U.S.
